[Activity of paclitaxel, epirubicin and carboplatin in patients with advanced or recurrent endometrial cancer].
Nakashima
Ryuichi
R
Department of Obstetrics and Gynecology, Faculty of Medicine, Osaka University.
Enomoto
Takayuki
T
Murata
Yuji
Y
Fujita
Masami
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000473:pathology / Q000628:therapy*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011182:Postoperative Care; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D015251:Epirubicin; D016190:Carboplatin; D017239:Paclitaxel